Febrile neutropenia
Reading File
Finding Sources
Searching PubMed
"febrile neutropenia" AND management
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I have all the MASCC table data and comprehensive management information. I now have enough from the textbooks to write a thorough answer. Let me compile everything into a well-organized response.
Febrile Neutropenia (FN)
Definition
Neutropenia is defined as an absolute neutrophil count (ANC) of:
- < 1000/mm³ - neutropenia (clinical decision threshold)
- < 500/mm³ - severe neutropenia (empiric antibiotics strongly indicated)
- < 100/mm³ - profound neutropenia
Fever is defined as:
- A single oral temperature ≥ 38.3°C (101°F), or
- Temperature ≥ 38.0°C (100.4°F) sustained for > 1 hour
Rectal temperatures are contraindicated in neutropenic patients due to theoretical risk of bacterial translocation.
Epidemiology and Causes
FN is most common in patients with hematologic malignancies compared to solid tumors, and typically occurs 7-10 days after chemotherapy (nadir). Neutropenia from chemotherapy usually resolves within 5 days after nadir. Risk depends on:
- Severity and duration of neutropenia
- Comorbidities (diabetes, liver/renal disease)
- Indwelling devices (central venous catheters)
Only ~50% of FN episodes have an identified source of fever. About 25% have a microbiologically confirmed source (blood, urine, wound cultures), and another 25% have a clinically evident source (e.g., pneumonia) without microbiologic confirmation.
- Rosen's Emergency Medicine, p. 3477
- Tintinalli's Emergency Medicine, p. 1557
Pathogens
| Category | Organisms | Clinical Note |
|---|---|---|
| Gram-positive (majority of serious infections) | MRSA, viridans streptococci, coagulase-negative staphylococci | Gram-positive organisms are most common but less immediately lethal |
| Gram-negative (most lethal) | Pseudomonas aeruginosa, E. coli, Klebsiella | Bacteremia is rapidly fatal - empiric coverage is mandatory |
| Anaerobes | Bacteroides, Clostridium | Consider with abdominal sources |
| Fungi | Candida, Aspergillus | Consider after prolonged neutropenia or failed antibiotics |
P. aeruginosa is the organism against which empiric coverage must always be included. - Goldman-Cecil Medicine, p. 3132
A special scenario: patients with chemotherapy-induced oral mucositis can develop rapid fever and shock due to viridans streptococci, which requires vancomycin. - Rosen's, p. 3477
Clinical Features and Pitfalls
Because neutrophils drive the inflammatory response, classic localizing signs of infection are often absent or muted:
- Pneumonia - may have no productive cough, no purulent sputum, and a normal initial CXR
- UTI - may have no pyuria
- Peritoneal infection - peritoneal signs may be absent
- Cellulitis - minimal induration, redness, or pus
- Perineal/anal infection - tenderness may be the only sign
Common Evaluation Pitfalls
- Assuming afebrile = no infection - some patients (on chronic prednisone, post-BMT, elderly) cannot mount a fever; clues may be tachycardia, tachypnea, mental status changes, metabolic acidosis, or hyperglycemia
- Overestimating CXR - infiltrates may be absent early in neutropenic pneumonia
- Missing colony-stimulating factor effect - patients given G-CSF may present with marked leukocytosis yet still be at FN risk
- Obtaining rectal temperature - contraindicated
- Digital rectal exam - relatively contraindicated until after initial antibiotics
Evaluation
History
- Previous FN episodes and prior culture results/sensitivities
- Current chemotherapy regimen and last dose date
- Recent travel, animal exposure, vaccinations
- Current antimicrobial prophylaxis (fluoroquinolone prophylaxis raises resistance risk)
- Colony-stimulating factor use
Physical Examination
Pay careful attention to areas commonly overlooked:
- Oral cavity (mucositis, thrush, herpes)
- Perianal area (tenderness, fissures, induration)
- IV/CVC entry sites (erythema, discharge, tenderness)
- Lungs, skin, nails, bone marrow aspiration sites, sinuses
Laboratory and Imaging
| Test | Indication |
|---|---|
| Two blood cultures | One from each CVC lumen + one peripheral, or two peripheral if no CVC |
| CBC, CMP, serum lactate | Baseline; assess renal/hepatic function |
| Urinalysis + urine culture | All patients |
| Chest radiograph | All patients (note poor sensitivity) |
| Sputum Gram stain/culture | Only if productive cough present |
| Stool culture + C. diff | Only if diarrhea present |
| Influenza PCR | Seasonal - PCR preferred over rapid antigen test |
| CT chest/abdomen/pelvis | Consider if no source found on routine evaluation |
| Lumbar puncture | Not routine; meningismus may be absent in FN |
- Rosen's Emergency Medicine, p. 3477
Risk Stratification
MASCC (Multinational Association for Supportive Care in Cancer) Index
| Clinical Characteristic | Score |
|---|---|
| Burden of illness: no or mild symptoms | 5 |
| Burden of illness: moderate symptoms | 3 |
| Burden of illness: severe symptoms | 0 |
| No hypotension (SBP > 90 mmHg) | 5 |
| No COPD | 4 |
| Solid tumor OR no prior fungal infection (in hematologic malignancy) | 4 |
| No dehydration requiring IV fluids | 3 |
| Outpatient status at time of fever onset | 3 |
| Age < 60 years | 2 |
Maximum score = 26. Score ≥ 21 = low risk.
- Goldman-Cecil Medicine, p. 2949
High-Risk Features (hospitalization required)
- Profound neutropenia (ANC < 100) or neutropenia expected to last > 7 days
- Comorbid medical conditions
- Acute liver or renal injury
- Hemodynamic instability / sepsis
- MASCC score < 21 or Clinical Index of Stable Febrile Neutropenia (CISNE) non-low-risk
Treatment
Antibiotics - Time Goal
Initiate empiric broad-spectrum antibiotics within 60 minutes of presentation.
Inpatient Empiric Regimens
Monotherapy (preferred unless specific indications for additions):
| Agent | Adult Dose | Notes |
|---|---|---|
| Piperacillin/tazobactam | 4.5 g IV q6h | Broad GP + Pseudomonas + anaerobes |
| Cefepime | 2 g IV q8h | GP + Pseudomonas + GN bacilli; no anaerobes |
| Ceftazidime | 2 g IV q8h | Primarily GN + Pseudomonas; less GP activity |
| Meropenem | 1 g IV q8h | Reserve for ESBL-producing organisms |
| Imipenem/cilastatin | 1 g IV q8h | Reserve for ESBL; note seizure risk |
If known ESBL colonization: use imipenem/cilastatin or meropenem.
Add Vancomycin in these specific situations:
- Hemodynamic instability / shock
- Suspected or confirmed catheter-related infection
- Skin/soft tissue infection
- Known MRSA colonization
- Severe mucositis
- Prior fluoroquinolone prophylaxis
- Institutions with frequent MRSA / viridans streptococci
Add Metronidazole if abdominal symptoms and using a non-anaerobic agent (e.g., cefepime).
Penicillin allergy:
- Severe allergy: aztreonam + vancomycin (avoid fluoroquinolones empirically for GN coverage)
- Minor allergy: cefepime, meropenem, or imipenem-cilastatin usually safe
Antifungal Therapy
- Not routinely indicated in the ED without infectious diseases consultation
- Consider empirical antifungals after 4-7 days of persistent fever despite antibiotics (persistent unexplained fever = possible invasive fungal infection)
Outpatient (Low-Risk) Regimen
| Agent | Dose |
|---|---|
| Ciprofloxacin 500 mg PO q12h | + amoxicillin/clavulanate 875/125 mg PO q12h |
| Levofloxacin 750 mg PO daily | + amoxicillin/clavulanate or clindamycin (if pen allergy) |
Outpatient therapy requires daily reassessment by a medical provider for the first 3 days and MASCC ≥ 21 with no other high-risk features. Observe for at least 4 hours after the initial antibiotic dose before discharge.
- Tintinalli's Emergency Medicine, p. 1558-1559
Duration of Therapy
- Continue empiric antibiotics for 2-4 days before assessing clinical response (unless culture results or clinical deterioration prompt earlier change)
- Median fever duration: ~2 days in low-risk; 5-7 days in high-risk patients
- Discontinue when: documented infection has clinically resolved AND patient has been afebrile for ≥ 2 days AND ANC > 500/mm³
Special Populations
Children with Febrile Neutropenia
- Pediatric cancer patients with FN should be transferred to a hospital experienced in pediatric oncology management
- A second prognostic score (SPOG - Swiss Pediatric Oncology Group) has been developed for pediatric use
Immunocompromised (Cell-Mediated Deficiency, e.g., post-BMT, chronic steroids)
- Broader pathogens: Listeria, Salmonella, Mycobacterium tuberculosis, Cryptococcus, Coccidioides, Histoplasma, HSV, VZV
- May not mount a fever at all - early empiric coverage is essential
Recent Evidence (2023-2025)
- A 2023 systematic review (PMID 37921996) supports ambulatory management for low-risk FN in adult oncology patients as safe and effective.
- A 2025 meta-analysis (PMID 40079575) on early antibiotic de-escalation in hematologic malignancy-associated FN found it to be both efficacious and safe - supporting the current practice of de-escalating after 2-4 days based on clinical response and culture results.
Summary: Key Clinical Pearls
- Fever is often the only sign - classic localizing findings are absent due to impaired inflammatory response
- Start antibiotics within 60 min - gram-negative bacteremia (especially P. aeruginosa) is rapidly fatal
- Monotherapy with an antipseudomonal beta-lactam is as effective as combination in most cases
- Vancomycin is not routine - add only for specific indications (shock, catheter infection, mucositis, MRSA)
- No rectal temps or rectal exams before antibiotics
- CXR and urinalysis are insensitive - absence of infiltrate or pyuria does not exclude pneumonia or UTI
- MASCC ≥ 21 + no high-risk features = candidate for outpatient management (consult oncology first)
- Antifungals are not an ED decision without ID consultation
Sources: Rosen's Emergency Medicine; Tintinalli's Emergency Medicine, p. 1557-1559; Goldman-Cecil Medicine, p. 2949-2951
This is a shared conversation. Sign in to Orris to start your own chat.